CSCI: Pendapatan dodolan perusahaan COSCIENS Biopharma

COSCIENS Biopharma Inc. is currently undergoing a cost optimization phase and a research portfolio review, which is fueling cautious optimism among investors. This revenue chart for the company on GURU.Markets reflects this trend, where the 0.01 mark records this metric. Stability is underpinned by exclusive drug distribution rights in Canada and LATAM, as well as the ownership of the Macrilen patent for diagnosing endocrine pathologies.

CSCI (COSCIENS Bio) riwayat Pendapatan lan volume dodolan saka 10.08.2024 nganti 14.09.2025

Rincian analitis perusahaan COSCIENS Biopharma Inc.

- rega saiki lan proyeksi nilai saham:

Kurs saham COSCIENS Bio|CSCI - Target konsensus

- informasi kapitalisasi pasar:

Nilai pasar COSCIENS Biopharma Inc.|CSCI - Nilai Total Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Buku Saham COSCIENS Biopharma|CSCI - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku cosciensbio.com|CSCI - Total Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal COSCIENS Biopharma Inc.|CSCI - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal COSCIENS Biopharma Inc|CSCI - Utang perusahaan|Utang marang nilai buku COSCIENS Biopharma Inc.|CSCI - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan COSCIENS Biopharma|Indikator likuiditas cepet cosciensbio.com

- indikator pendapatan resik lan kelipatan nilai:

CSCI - Bathi resik perusahaan|Bathi resik sing dikarepake COSCIENS Biopharma Inc.|CSCI - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi cosciensbio.com|CSCI - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan COSCIENS Biopharma Inc.|CSCI - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan COSCIENS Biopharma|CSCI - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan cosciensbio.com|CSCI - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep COSCIENS Biopharma Inc.

- statistik dodolan lan pendapatan perusahaan:

CSCI - Pendapatan perusahaan|Dodolan mangsa ngarep perusahaan COSCIENS Bio|CSCI - Kapitalisasi marang pendapatan|Rega forward marang dodolan COSCIENS Biopharma Inc.

Analisis komprehensif perusahaan:CSCI COSCIENS Bio

The monetization of unique patents in the orphan endocrinology segment allows COSCIENS Biopharma Inc. (CSCI) to maintain high margins due to inelastic demand. The trend in the company's aggregate sales figures reflects daily cash inflows, verifying the business's operational resilience and eliminating the risk of reporting manipulation, which makes this chart a key tool for assessing the issuer's financial security.

Pesaing wigati